Medistim ASA (MEDS.OL) Key Developments | Reuters.com
Edition:
United States

Medistim ASA (MEDS.OL)

MEDS.OL on Oslo Stock Exchange

56.00NOK
24 Jun 2016
Change (% chg)

kr1.00 (+1.82%)
Prev Close
kr55.00
Open
kr51.50
Day's High
kr56.00
Day's Low
kr51.50
Volume
4,064
Avg. Vol
12,343
52-wk High
kr65.00
52-wk Low
kr35.60

Latest Key Developments (Source: Significant Developments)

Medistim proposes 2015 dividend of NOK 1.65/share
Monday, 29 Feb 2016 10:14am EST 

Medistim ASA:Says ‍board suggests dividend of 1.65 Norwegian crown per share for 2015.Paid dividend of 1.40 crown per share for 2014​.  Full Article

Medistim launches its new product MiraQ in US
Friday, 22 Jan 2016 03:00am EST 

Medistim ASA:Announces that they launch its new product MiraQ in the US market.The launch takes place at the annual US Conference arranged by The Society of Thoracic Surgeons, STS, which takes place in Phoenix, Arizona, USA from the 23-27 Jan.Is seeking approval from the Ministry of Health, Labor and Welfare (MHLW) for clearance in the Japanese market and the health authorities in China, China Food and Drug Administration (CFDA) for clearance for sale in China.It is expected that these approvals will be in place by 2016.  Full Article

Blue Cap 's unit em-tec and Medistim ASA to start international cooperation
Tuesday, 27 Oct 2015 03:01am EDT 

Blue Cap AG:Subsidiary em-tec and Medistim ASA to start international cooperation.Medistim to receive from em-tec exclusive and worldwide marketing rights for products developed for non-invasive flow measurement of human blood vessels.Financial terms of contract include upfront payment of 300,000 euros and life-time minimum order of 1.4 million euros.  Full Article

Medistim ASA enters into a strategic partnership with em-tec GmbH
Thursday, 22 Oct 2015 01:10pm EDT 

Medistim ASA:Says entered into a long-term agreement with em-tec GmbH.Obtains rights to market and sell em-tec's transit time flow measurement technology for use on human blood vessels within cardiac-, vascular- and transplant surgery.Upfront payment of about 300,000 euros and minimum purchase commitments.  Full Article

Medistim introduces new specialized product for vascular surgery
Wednesday, 23 Sep 2015 03:45am EDT 

Medistim ASA:Introduces its new specialized product for vascular surgery.Medistim estimate that vascular market has an annual potential of 1 billion Norwegian crowns.  Full Article

Medistim launches MiraQ Cardiac system in Asia
Tuesday, 2 Jun 2015 08:00pm EDT 

Medistim ASA:Says Medistim is in the process of launching MiraQ Cardiac system in the Asian Market.  Full Article

Medistim ASA: Annulment of merger for Medistim second largest shareholder
Thursday, 19 Mar 2015 07:32am EDT 

Medistim ASA:Annulment of reported mother-daughter merger for Medistim second largest shareholder Salvesen & Thams Invest AS.Says boards of Salvesen & Thams Invest AS and Salvesen & Thams AS has decided that merger will not be implemented.  Full Article

Medistim ASA proposes FY 2014 dividend of 1.40 Norwegian crown per share
Thursday, 26 Feb 2015 01:55am EST 

Medistim ASA:Proposes 2014 dividend of 1.40 crown/earnings per share.  Full Article

Medistim clearance for sale of VeriQ C in China
Thursday, 19 Feb 2015 05:40am EST 

Medistim ASA:Medistim has received clearance for sale of VeriQ C in China.Says received clearance from China Food and Drug Administration (CFDA) for sale of its product VeriQ C.  Full Article

Medistim ASA's subsidiary Medistim Norge AS wins nationwide tender
Thursday, 6 Nov 2014 06:32am EST 

Medistim ASA:Says Medistims subsidiary Medistim Norge AS has won nationwide tender for breast implants.Says tender for breast implants was organized by HINAS (Helseforetakenes innkjopsservice AS).Says agreement with HINAS starts Jan. 1, 2015 and will last initially for 2 years, with the possibility of 2 years extension.Says agreement size is estimated to be 8 to 10 million Norwegian crowns per year.  Full Article

BRIEF-Medistim Q1 operating profit NOK 13.5 mln, up 37.2%

* Q1 sales ended at 65.5 million Norwegian crowns an increase of 13.1 pct